TrialHaematologica2020

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.

Anders Lindholm Sørensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.